Across TCGA pan-cancer cohorts, HBZ Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated HBZ data layer compared with 15 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher HBZ Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HBZ expression acts as an unfavorable survival marker.
HNSC and UCEC are the cancer types where HBZ Mutation most reproducibly stratifies survival.